308 related articles for article (PubMed ID: 25015594)
21. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
Zeng Z; Choi DS; Mohan V; Emser A; Siddiqui K; Gong Y; Patel S; Woerle HJ
Curr Med Res Opin; 2015 Jan; 31(1):99-106. PubMed ID: 25215428
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
[TBL] [Abstract][Full Text] [Related]
24. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
Groop PH; Del Prato S; Taskinen MR; Owens DR; Gong Y; Crowe S; Patel S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2014 Jun; 16(6):560-8. PubMed ID: 24612167
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.
Davidson JA; Lajara R; Aguilar RB; Mattheus M; Woerle HJ; von Eynatten M
BMJ Open Diabetes Res Care; 2014; 2(1):e000020. PubMed ID: 25452864
[TBL] [Abstract][Full Text] [Related]
26. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
[TBL] [Abstract][Full Text] [Related]
28. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.
Mikhail N
Curr Drug Saf; 2011 Nov; 6(5):304-9. PubMed ID: 22424537
[TBL] [Abstract][Full Text] [Related]
29. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
30. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Barnett AH; Charbonnel B; Moses RG; Kalra S
Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
[TBL] [Abstract][Full Text] [Related]
31. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
33. Linagliptin: in type 2 diabetes mellitus.
Scott LJ
Drugs; 2011 Mar; 71(5):611-24. PubMed ID: 21443284
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
[TBL] [Abstract][Full Text] [Related]
35. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
Schweizer A; Dejager S; Foley JE; Kothny W
Vasc Health Risk Manag; 2011; 7():49-57. PubMed ID: 21415917
[TBL] [Abstract][Full Text] [Related]
36. The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial.
Tripolt NJ; Aberer F; Riedl R; Hutz B; Url J; Dimsity G; Meinitzer A; Stojakovic T; Hödl R; Brodmann M; Hafner F; Sourij H
Trials; 2016 Oct; 17(1):495. PubMed ID: 27733180
[TBL] [Abstract][Full Text] [Related]
37. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Laakso M; Rosenstock J; Groop PH; Barnett AH; Gallwitz B; Hehnke U; Tamminen I; Patel S; von Eynatten M; Woerle HJ
Diabetes Care; 2015 Feb; 38(2):e15-7. PubMed ID: 25614693
[No Abstract] [Full Text] [Related]
38. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Tiwari A
Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
[TBL] [Abstract][Full Text] [Related]
39. Review of linagliptin for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Setter SM
Clin Ther; 2012 May; 34(5):993-1005. PubMed ID: 22440191
[TBL] [Abstract][Full Text] [Related]
40. Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.
von Websky K; Reichetzeder C; Hocher B
Vasc Health Risk Manag; 2013; 9():681-94. PubMed ID: 24204157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
